Literature DB >> 1832237

Immune response to hepatitis B virus proteins: relevance of the murine model.

D R Milich1.   

Abstract

The experimental murine models offer unique opportunities to study the genetic, cellular, and molecular basis for variable immune responsiveness to HBV-encoded antigens. The mouse has provided a means of studying the immunogenicity of the pre-S regions of HBsAg and has elucidated the independent H-2-linked genes regulating antibody production to pre-S and S region determinants. The ability to circumvent genetic nonresponsiveness has implications for the design of future HBV vaccines. Mice also afforded the opportunity to examine the ability of HBcAg to activate B cells directly, and to prime Th cells capable of eliciting antibody to envelope proteins. These observations have potential clinical relevance, implications for vaccine design, and may explain the ability of HBcAg vaccination to protect against HBV infection. The murine system ha also facilitated the mapping of T-cell and B-cell recognition sites within HBV proteins, which at least conceptually enhances the prospects for development of a synthetic HBV vaccine. Antibody-binding sites appear to be similar in humans and mice; the extent to which their T-cell repertoires overlap is not known. However, the chemical and structural constraints imposed on T-cell antigenicity, and the fact that MHC-encoded class II molecules and the cellular mechanisms mediating T-cell recognition are conserved across species, make such overlaps appear likely. Furthermore, the ability to generate transgenic mice that express the various HBV proteins has yielded important insights into possible immunopathogenic mechanism and immunologic tolerance mechanisms that may predispose to chronic infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832237     DOI: 10.1055/s-2008-1040428

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  18 in total

1.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

3.  Association between frequency of amino acid changes in core region of hepatitis B virus (HBV) and the presence of precore mutation in Japanese HBV carriers.

Authors:  T Karasawa; T Shirasawa; Y Okawa; A Kuramoto; N Shimada; Y Aizawa; M Zeniya; G Toda
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

4.  Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

Authors:  S L Tsai; P J Chen; M Y Lai; P M Yang; J L Sung; J H Huang; L H Hwang; T H Chang; D S Chen
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

5.  Analysis of human T-cell antigen receptor variable beta gene usage following vaccination with recombinant HBsAg.

Authors:  K Yuh; S Sugyo; K Nakamura; H Shijo; K Emi; K Harada; S Yoshitake; N Kimura; T Moribe; T Kaneshige; M Okumura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

6.  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice.

Authors:  Yingjie Bian; Zheng Zhang; Zhichen Sun; Juanjuan Zhao; Danming Zhu; Yang Wang; Sherry Fu; Jingya Guo; Longchao Liu; Lishan Su; Fu-Sheng Wang; Yang-Xin Fu; Hua Peng
Journal:  Hepatology       Date:  2017-08-26       Impact factor: 17.425

7.  CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.

Authors:  E Malanchère-Brès; P J Payette; M Mancini; P Tiollais; H L Davis; M L Michel
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro.

Authors:  H M Diepolder; M C Jung; E Wierenga; R M Hoffmann; R Zachoval; T J Gerlach; S Scholz; G Heavner; G Riethmüller; G R Pape
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

9.  Intrahepatic mononuclear cell populations and MHC antigen expression in patients with chronic hepatitis C [correction of B]: effect of interferon-alpha.

Authors:  D H Van Thiel; X Zhang; N Baddour; H I Wright; L Friedlander; J S Gavaler
Journal:  Dig Dis Sci       Date:  1994-05       Impact factor: 3.199

10.  Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes.

Authors:  S L Tsai; M H Chen; C T Yeh; C M Chu; A N Lin; F H Chiou; T H Chang; Y F Liaw
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.